DK2971039T3 - Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer - Google Patents
Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer Download PDFInfo
- Publication number
- DK2971039T3 DK2971039T3 DK14768084.7T DK14768084T DK2971039T3 DK 2971039 T3 DK2971039 T3 DK 2971039T3 DK 14768084 T DK14768084 T DK 14768084T DK 2971039 T3 DK2971039 T3 DK 2971039T3
- Authority
- DK
- Denmark
- Prior art keywords
- pseudotype
- vsv
- transduction
- cells
- memory
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 230000004069 differentiation Effects 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000026683 transduction Effects 0.000 title 1
- 238000010361 transduction Methods 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/231—Interleukin-10 (IL-10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785490P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027910 WO2014152832A1 (en) | 2013-03-14 | 2014-03-14 | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2971039T3 true DK2971039T3 (da) | 2020-04-06 |
Family
ID=51581331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14768084.7T DK2971039T3 (da) | 2013-03-14 | 2014-03-14 | Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10240125B2 (da) |
| EP (1) | EP2971039B1 (da) |
| JP (5) | JP6392315B2 (da) |
| CA (1) | CA2906674C (da) |
| DK (1) | DK2971039T3 (da) |
| ES (1) | ES2786253T3 (da) |
| HK (1) | HK1220230A1 (da) |
| PT (1) | PT2971039T (da) |
| WO (1) | WO2014152832A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2971039T3 (da) * | 2013-03-14 | 2020-04-06 | Immusoft Corp | Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer |
| EP4177336A1 (en) | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| EP3307070A4 (en) * | 2015-06-12 | 2019-01-02 | Emory University | Growth and survival compositions for cells capable of producing antibodies and methods related thereto |
| CA3041527C (en) * | 2016-10-23 | 2023-09-05 | Berkeley Lights, Inc. | Methods for screening b cell lymphocytes |
| US20220193129A1 (en) * | 2017-04-27 | 2022-06-23 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents and dosages thereof |
| US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
| EP3765601A1 (en) | 2018-03-16 | 2021-01-20 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| WO2021102308A1 (en) * | 2019-11-21 | 2021-05-27 | Emulate Inc. | Antibody producing microfluidic devices |
| KR102539610B1 (ko) * | 2020-01-22 | 2023-06-02 | 한국생명공학연구원 | 메모리 b 세포 특이적 분화 유도 방법 및 이의 활용 |
| WO2023086639A1 (en) * | 2021-11-11 | 2023-05-19 | The General Hospital Corporation | Methods for defining stages and progression of amyotrophic lateral sclerosis |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0276820A (ja) | 1988-06-15 | 1990-03-16 | Ajinomoto Co Inc | 骨髄移植療法支持剤 |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5057423A (en) | 1987-12-18 | 1991-10-15 | University Of Pittsburgh | Method for the preparation of pure LAK-active lymphocytes |
| US5124259A (en) | 1989-08-23 | 1992-06-23 | Mitsui Toatsu Chemicals, Inc. | Method for electroporation |
| DE4223128C2 (de) | 1991-07-15 | 1995-06-14 | Handtmann Albert Maschf | Verfahren und Vorrichtung zum Vereinzeln und Aufbringen einer Darmraupe auf ein Füllrohr |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| EP0938893B1 (en) | 1993-08-10 | 2004-08-25 | W.L. Gore & Associates, Inc. | Cell encapsulating device |
| ES2375561T3 (es) | 1994-01-11 | 2012-03-02 | Dyax Corporation | Inhibidores de la plasmina humana derivados de dominios kunitz y �?cidos nucleicos que codifican los mismos. |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| EP0773753B1 (en) | 1995-06-07 | 2003-10-08 | Gore Hybrid Technologies, Inc. | An implantable containment apparatus for a therapeutical device |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7301010B2 (en) | 2001-02-15 | 2007-11-27 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating HIV infection with cupredoxin and cytochrome c |
| US7556810B2 (en) | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
| US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7338766B2 (en) | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| US7084105B2 (en) | 2001-02-15 | 2006-08-01 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| CA2438500C (en) | 2001-02-19 | 2009-09-08 | Pola Chemical Industries Inc. | Composition for electroporation |
| CN100575485C (zh) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | 使用锌指核酸酶的定向染色体诱变 |
| EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP1581610A4 (en) | 2002-09-05 | 2009-05-27 | California Inst Of Techn | USE OF CHIMERIC NUCLEASES TO STIMULATE GENE TARGETING |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| WO2006029196A1 (en) * | 2004-09-08 | 2006-03-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth | Transcytosis of adeno-associated viruses |
| WO2006033859A2 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| ATE414718T1 (de) | 2005-01-05 | 2008-12-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| CA2538208A1 (en) | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
| DK1945762T3 (da) | 2005-10-18 | 2013-07-29 | Prec Biosciences | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
| CA2629647C (en) | 2005-11-17 | 2013-05-21 | Biogen Idec Ma Inc. | Platelet aggregation assays |
| NZ569543A (en) | 2005-12-09 | 2012-12-21 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| US7799555B2 (en) | 2006-02-10 | 2010-09-21 | Bio-Rad Laboratories, Inc. | Apparatus for high-throughput electroporation |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| EP2205752B1 (en) | 2007-10-25 | 2016-08-10 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
| US8551780B2 (en) | 2008-02-01 | 2013-10-08 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Electroporation buffer composition and method of use |
| EP2281050B1 (en) | 2008-04-14 | 2014-04-02 | Sangamo BioSciences, Inc. | Linear donor constructs for targeted integration |
| WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| US8133727B2 (en) | 2008-11-21 | 2012-03-13 | California Institute Of Technology | In vitro human B lymphopoiesis culture system |
| WO2011085247A2 (en) * | 2010-01-08 | 2011-07-14 | Immusoft Corporation | Vectors and methods for transducing b cells |
| CA2788850C (en) | 2010-02-09 | 2019-06-25 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| KR101637933B1 (ko) | 2010-03-15 | 2016-07-08 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 포유동물 세포로의 유전자 도입효율의 향상제 |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| SI2400298T1 (sl) | 2010-05-28 | 2013-11-29 | F. Hoffmann-La Roche Ag | Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles |
| CA2806858C (en) | 2010-08-04 | 2021-06-15 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| IN2014MN01420A (da) | 2011-12-14 | 2015-04-03 | Yeda Res & Dev | |
| EA201590719A1 (ru) | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
| DK2971039T3 (da) | 2013-03-14 | 2020-04-06 | Immusoft Corp | Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| US10842886B2 (en) | 2014-10-10 | 2020-11-24 | Research Institute At Nationwide Children's Hospital | Guided injections for AAV gene transfer to muscle |
| EP4177336A1 (en) | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| EP4335918A3 (en) | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| HRP20220050T1 (hr) | 2015-05-15 | 2022-10-14 | Regents Of The University Of Minnesota | Adenoasocirani virus, namijenjen terapijskom unosu u središnji živčani sustav |
| EP3765601A1 (en) | 2018-03-16 | 2021-01-20 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
-
2014
- 2014-03-14 DK DK14768084.7T patent/DK2971039T3/da active
- 2014-03-14 WO PCT/US2014/027910 patent/WO2014152832A1/en active Application Filing
- 2014-03-14 JP JP2016502661A patent/JP6392315B2/ja active Active
- 2014-03-14 US US14/776,283 patent/US10240125B2/en active Active
- 2014-03-14 ES ES14768084T patent/ES2786253T3/es active Active
- 2014-03-14 CA CA2906674A patent/CA2906674C/en active Active
- 2014-03-14 EP EP14768084.7A patent/EP2971039B1/en active Active
- 2014-03-14 PT PT147680847T patent/PT2971039T/pt unknown
-
2016
- 2016-07-12 HK HK16108108.4A patent/HK1220230A1/zh unknown
-
2018
- 2018-02-07 JP JP2018020269A patent/JP6689897B2/ja active Active
-
2019
- 2019-02-04 US US16/267,150 patent/US11352603B2/en active Active
-
2020
- 2020-01-30 JP JP2020013376A patent/JP2020062058A/ja not_active Withdrawn
-
2022
- 2022-01-31 JP JP2022012823A patent/JP7499798B2/ja active Active
- 2022-05-03 US US17/735,676 patent/US20230013198A1/en active Pending
-
2023
- 2023-06-08 JP JP2023094831A patent/JP2023105218A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10240125B2 (en) | 2019-03-26 |
| JP6689897B2 (ja) | 2020-04-28 |
| HK1220230A1 (zh) | 2017-04-28 |
| EP2971039A4 (en) | 2016-10-12 |
| US20190241870A1 (en) | 2019-08-08 |
| WO2014152832A1 (en) | 2014-09-25 |
| JP2018075039A (ja) | 2018-05-17 |
| JP2023105218A (ja) | 2023-07-28 |
| US11352603B2 (en) | 2022-06-07 |
| EP2971039A1 (en) | 2016-01-20 |
| US20160046908A1 (en) | 2016-02-18 |
| ES2786253T3 (es) | 2020-10-09 |
| JP2020062058A (ja) | 2020-04-23 |
| JP2022048252A (ja) | 2022-03-25 |
| JP7499798B2 (ja) | 2024-06-14 |
| CA2906674C (en) | 2023-01-10 |
| CA2906674A1 (en) | 2014-09-25 |
| PT2971039T (pt) | 2020-05-06 |
| JP6392315B2 (ja) | 2018-09-19 |
| US20230013198A1 (en) | 2023-01-19 |
| JP2016513476A (ja) | 2016-05-16 |
| EP2971039B1 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2971039T3 (da) | Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer | |
| DK3421590T3 (da) | Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet | |
| DK2953969T3 (da) | Anti-IL-17A-antistoffer og deres anvendelse til behandling af autoimmune og inflammatoriske forstyrrelser | |
| DK3462569T3 (da) | Batteri og ubemandet luftfartøj med batteri | |
| DK2970398T3 (da) | Præfusions-rsv-f-proteiner og anvendelse deraf | |
| DK3083616T3 (da) | Bicykliske heterocykliske forbindelser og disses anvendelser i terapi | |
| DK3044320T3 (da) | Sekretion af hæmholdige polypeptider | |
| DK3421486T5 (da) | Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser | |
| DK2970898T3 (da) | Fremstilling og anvendels af røde blodceller | |
| DK3322425T3 (da) | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi | |
| DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
| DK3409083T3 (da) | Forbedringer af og i forbindelse med datacentre | |
| DK3200791T3 (da) | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister | |
| DK2805670T3 (da) | Forbedringer af og i sammenhæng med oftalmoskoper | |
| DK3065759T3 (da) | Immunosuppressive midler og deres anvendelse i terapi | |
| DK3303778T3 (da) | Forbedringer i energiopbevaring | |
| DK2970843T3 (da) | Fremgangsmåder til frembringelse af cellebank med høj densitet | |
| DK2955777T3 (da) | Brændselscelle og fremgangsmåde til fremstilling af samme | |
| DK3269809T3 (da) | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF | |
| DK3104717T3 (da) | Saccharosereduktion og generering af uopløselige fibre i juice | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| DK3619362T3 (da) | Forbedringer af og i forbindelse med barrierer | |
| DK3297063T3 (da) | Kompositmembran og lithium-ion-batteri dermed | |
| DK2880053T3 (da) | Lindring af vævsskade og fibrose via anti-LTBP4-antistof | |
| DK3131577T3 (da) | Modificerede værtsceller og anvendelser deraf |